Janssen Pharmaceutica Nv

Janssen Pharmaceutica

Brad M Savall

Michael Anthony Letavic

Devin M Swanson

Brock T Shireman

Akinola Soyode-Johnson

Chandravadan R Shah

Dale A Rudolph

Curt A Dvorak

Heather Renee Coate

Christine Fang Gelin

Brice M Stenne

Christa C Chrovian

Kiev S Ly

Manuel Jesus Alcazar Vaca

Jose Ignacio Andres Gil

Meri De Angelis

James Patrick Edwards

Daniel J Pippel

Wenying Chai

Michael K Ameriks

Emily M Stocking

Frank Chavez

Kathleen C Sappey

Jason Christopher Rech

Akinola Soyode Johnson

Ronald L Wolin

Jianmei Wei

Brian Ngo Laforteza

Cheryl A Grice

Neelakandha S Mani

Warren Stanfield Wade

Steven P Meduna

Laurent Gomez

Hui Cai

Bryan James Branstetter

Michael P Curtis

Kevin L Tays

Terry Patrick Lebold

Suchitra Ravula

Jessica L Wall

Robin L Thurmond

Aaron M Kearney

Xiaohu Zhang

Stephen Todd Meyer

Márió Gyuris

Paul J Dunford

Andrew J Greenspan

Jorge A Quiroz

Jennifer Diane Venable

Jing Liu

Xiaohu Deng

Brett D Allison

Jimmy T Liang

Anne E Fitzgerald

János Gerencsér

Michael K Americks

Kathleen C Strother

Michael A Letavic

Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

P2X7 modulators

The present invention is directed to compounds of Formulas (I, IIa and IIb):  The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Fused azaheterocyclic compounds and their use as AMPA receptor modulators

The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention. 

P2X7 modulators and methods of use

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof,  Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators

Fused bicylic pyridine compounds and their use as AMPA receptor modulators

The present invention is directed to a compound of Formula (I). The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) and methods comprising administering to a subject at least one compound selected from compounds of Formula (I) for treating diseases mediated by P2X7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, Parkinson's disease, schizophrenia, Alzheimer's disease, Huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, Crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, Polycystic Kidney Disease, Glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, Amyotrophic Lateral Sclerosis, Chaga's Disease,, neuroblastoma, Tuberculosis, and migraine. 

Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators

The present invention is directed to a compound of Formula (I) and to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

Growing community of inventors

San Diego, CA, United States of America

Brad M Savall